These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11930465)

  • 21. Home versus in-patient treatment for deep vein thrombosis.
    Othieno R; Abu Affan M; Okpo E
    Cochrane Database Syst Rev; 2007 Jul; (3):CD003076. PubMed ID: 17636714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low molecular weight heparin for outpatient treatment of venous thromboembolism. safe, effective, and cost reducing?
    Koopman MM; Bossuyt PM
    Am J Med; 2003 Sep; 115(4):324-5. PubMed ID: 12967699
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of venous thromboembolism: optimization by clinical trials.
    Turpie AG
    Haemostasis; 1996 Oct; 26 Suppl 4():220-6. PubMed ID: 8979127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.
    Gómez-Outes A; Rocha E; Martínez-González J; Kakkar VV
    Pharmacoeconomics; 2006; 24(1):81-92. PubMed ID: 16445305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin.
    de Lissovoy G; Yusen RD; Spiro TE; Krupski WC; Champion AH; Sorensen SV
    Arch Intern Med; 2000 Nov; 160(20):3160-5. PubMed ID: 11074747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects.
    Hull RD; Pineo GF; Raskob GE
    Haemostasis; 1998; 28 Suppl 3():8-16. PubMed ID: 10069757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prophylaxis of postoperative thromboembolism. New alternatives to low-molecular-weight heparin].
    Bergqvist D; Siegbahn A
    Lakartidningen; 2002 Jul; 99(28-29):3039-41. PubMed ID: 12170516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-molecular weight heparins in venous and arterial thrombotic disease.
    Bijsterveld NR; Hettiarachchi R; Peters R; Prins MH; Levi M; Büller HR
    Thromb Haemost; 1999 Sep; 82 Suppl 1():139-47. PubMed ID: 10695506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: preliminary data.
    Wade WE; Spruill WJ
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):619-25. PubMed ID: 11734661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparin in the treatment of deep venous thrombosis.
    Hauer KE
    West J Med; 1998 Oct; 169(4):240-4. PubMed ID: 9795594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Home treatment of deep vein thrombosis. An out-patient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients.
    Lapidus L; Börretzen J; Fahlén M; Thomsen HG; Hasselblom S; Larson L; Nordström H; Stigendal L; Waller L
    Pathophysiol Haemost Thromb; 2002; 32(2):59-66. PubMed ID: 12214150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does low-molecular-weight heparin reduce the costs of venous thromboembolism treatment?
    Bossuyt PM; Prins MH
    Haemostasis; 2000; 30 Suppl 2():136-40; discussion 128-9. PubMed ID: 11251358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of deep vein thrombosis with low molecular weight heparins at home].
    Suárez Alvarez CG; García Cañete J; Herrero Mendoza MD; Bellver Alvarez TM; Arboiro Pinel R
    An Med Interna; 2003 Mar; 20(3):134-6. PubMed ID: 12756898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Home versus in-patient treatment for deep vein thrombosis.
    Schraibman IG; Milne AA; Royle EM
    Cochrane Database Syst Rev; 2001; (2):CD003076. PubMed ID: 11406067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    van Den Belt AG; Prins MH; Lensing AW; Castro AA; Clark OA; Atallah AN; Burihan E
    Cochrane Database Syst Rev; 2000; (2):CD001100. PubMed ID: 10796593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis.
    O'Brien B; Levine M; Willan A; Goeree R; Haley S; Blackhouse G; Gent M
    Arch Intern Med; 1999 Oct; 159(19):2298-304. PubMed ID: 10547169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
    Cheer SM; Dunn CJ; Foster R
    Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.